Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
31 hedge funds and large institutions have $1.55M invested in Statera Biopharma, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
11% less funds holding
Funds holding: 35 → 31 (-4)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
53% less capital invested
Capital invested by funds: $3.32M → $1.55M (-$1.77M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.7K |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$8.76K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$2.92K |
| 4 |
Morgan Stanley
New York
|
+$584 |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$549 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$888K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$89K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$24K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$17.8K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $393 | – | – | – |
|
|
AIG
27
American International Group
New York
| $240 | – | – | – |
|
|
BFA
28
BlackRock Fund Advisors
San Francisco,
California
| – | -$89K | -6,498 | Closed |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$24K | -1,750 | Closed |
|
|
OC
30
Oppenheimer & Co
New York
| – | -$17K | -1,275 | Closed |
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$12K | -885 | Closed |
|
32
Citigroup
New York
| – | -$8K | -605 | Closed |
|
33
Creative Planning
Overland Park,
Kansas
| – | -$1K | -50 | Closed |
|
|
34
Ameriprise
Minneapolis,
Minnesota
| – | +$549 | +47 | +1,567% |
|
|
TDC
35
Thompson Davis & Co
Richmond,
Virginia
| – | +$2.92K | +250 | New |
|
|
PRCM
36
Pine River Capital Management
Minnetonka,
Minnesota
| – | +$8.76K | +750 | New |
|
STAB Hedge Fund Activity: Q2 2014 in Review
31 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2014, worth a combined $1.55M — down 53% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STAB and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $19.7K. The largest seller was Sabby Management, cutting an estimated $888K.
- 31 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2014, down from 35 in Q1 2014.
- Funds reported $1.55M of Statera Biopharma, Inc. Common Stock stock for Q2 2014, down 53% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2014 and 6 closed out, a net change of -4 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2014 was Vanguard Group, an estimated $19.7K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2014 was Sabby Management, an estimated $888K sold.
Based on aggregated 13F filings for Q2 2014.